Figure 2

Incidence of neuropathic toxicities reported during first-line docetaxel (D)–carboplatin (C) therapy in a dose-finding study of D 60–85 mg m⁻² and C AUC 5–7 in women with ovarian cancer (139 evaluable for safety) (Vasey et al, 2001).